In vivo assessment of mitochondrial toxicity of metacavir in Rhesus monkeys after three months of intravenous administration

Acta Pharmacologica Sinica

Volumn 30, Issue 12, 2009, Pages 1666-1673

  Zeng, Wen ^a,c   Cheng, An Chun ^a,d   Chen, Zheng Li ^a,d   Luo, Qi Hui ^a,d   Sun, Yu Bo ^c   Li, Zhan ^b   Bi, Feng Jun ^a  

^a SICHUAN AGRICULTURAL UNIVERSITY   (China)

^b Nanjing chang'Ao Pharmaceutical Science and Technology Co Ltd   (China)

^c Sinopharm Center for Safety Evaluation and Research   (China)

^d Key Laboratory of Animal Disease and Human Health of Sichuan Province   (China)

Author keywords

Metacavir; Mitochondria; MtDNA; Respiratory chain; Rhesus monkey; Toxicity

Indexed keywords

METACAVIR; MITOCHONDRIAL DNA; NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DNA CONTENT; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; ELECTRON MICROSCOPE; FEMALE; HEART MITOCHONDRION; HEART MUSCLE INJURY; IN VIVO STUDY; KIDNEY; LIVER INJURY; LIVER MITOCHONDRION; MALE; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MITOCHONDRION; MUSCLE MITOCHONDRION; NONHUMAN; REPEATED DRUG DOSE; RESPIRATORY CHAIN; RHESUS MONKEY; SKELETAL MUSCLE; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT WITHDRAWAL;

ANIMALS; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT COMPLEX I; ELECTRON TRANSPORT COMPLEX II; FEMALE; HEART; INJECTIONS, INTRAVENOUS; KIDNEY; LIVER; MACACA MULATTA; MALE; MITOCHONDRIA; MUSCLE, SKELETAL; MYOCARDIUM; PURINE NUCLEOSIDES; ZIDOVUDINE;

EID: 74949094493     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.163     Document Type: Article

References (30)

1. Janssen HL, van Zonneveld M, Schalm SW. Hepatitis B. N Engl J Med 2004; 350: 2719-2720
2. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001; 77: 158-173
3. Kees Brinkman, Hadewych J M ter Hofstede. Mitochondrial toxicity of nucleoside analogue reverse trancriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev 1999; 1: 140-146
4. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716-723 (Pubitemid 34157656)
5. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-1744
6. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-1430
7. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; 6: 9-20.
8. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22: 911-936 (Pubitemid 30671584)
9. Lewis W, Copeland WC, Day BJ. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest 2001; 81: 777-790
10. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508-510
11. Masanés F, Barrientos A, Cebrián M, Pedrol E, Miró O, Casademont J, et al. Clinical, histological and molecular reversibility of zidovudine myopathy. J Neurol Sci 1998; 159: 226-228
12. Pezeshkpour G, Illa I, Dalakas MC. Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine- associated myopathies. Hum Pathol 1991; 22: 1281-1288
13. Lewis W, Gonzalez B, Chomyn A, Papoian T. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest 1992; 89: 1354-1360
14. Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier M, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med 1994; 235: 367-371
15. Dubinsky RM, Yarchoan R, Dalakas M, Broder S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2,3- dideoxycytidine (ddC). Muscle Nerve 1989; 12: 856-860
16. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133: 192-196
17. Gerschenson M, Erhart SW, Paik CY, St Claire MC, Nagashima K, Skopets B, et al. Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in Utero to 3-azido- 3-deoxythymidine. AIDS Res Hum Retroviruses 2000; 16: 635-644
18. Li Z, Huang X, Jiang Z, Xiao Y, Liu C, Zhang L, et al. A sensitive and specific liquid chromatography-mass spectrometry method for determination of metacavir in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 864: 9-14.
19. Biesecker G, Karimi S, Desjardins J, Meyer D, Abbott B, Bendele R, et al. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antiviral Research 2003; 58: 217-225
20. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 2165-2173
21. Richardson FC, Tennant BC, Meyer DJ, Richardson KA, Mann PC, McGinty GR, et al. An evaluation of the toxicities of 2'-fluorouridine and 2'-fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax). Toxicol Pathol 1999; 27: 607-617
22. Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, et al. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 1998: 28: 179-191
23. Bishop JB, Tani Y, Witt K, Johnson JA, Peddada S, Dunnick J, et al. Mitochondrial damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicological sciences 2004; 81: 512-517
24. Chan SS, Santos JH, Meyer JN, Mandavilli BS, Cook DL Jr, McCash CL, et al. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. Environmental and molecular mutagenesis 2007; 48: 190-200.
25. Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008; 52: 598-605.
26. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708.
27. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38: 2743-2749
28. Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811-820
29. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-1089 (Pubitemid 29452821)
30. Morton DM. Importance of species selection in drug toxicity testing. Toxicol Lett 1998; 102-103: 545-550